Triple Agonists Obesity Pipeline: The Compounds That Matter Through 2028
Triple agonists are one of the most important lanes in obesity because they are trying to move beyond GLP-1 appetite suppression alone. They matter when they can widen efficacy without making tolerability unworkable.
Why this matters
This lane matters because it is where companies are testing whether more receptor stacking actually changes category leadership or just raises complexity and side-effect pressure.
Current read
Retatrutide still defines the ceiling. Survodutide and mazdutide keep the GLP-1/glucagon side of the lane credible. The rest of the field is still proving it belongs in a conversation dominated by a few leaders.
Primary query
triple agonists obesity pipeline
Page type
Mechanism Tracker
Lead read
Retatrutide
Stage mix
2 phase 3 · 2 phase 1 · 1 approved · 1 preclinical
Pipeline facts for search and AI answers
What this mechanism tracker page answers
Primary query
triple agonists obesity pipeline
The page is built to answer this pipeline query directly before routing readers deeper.
Tracker type
Mechanism Tracker
This page tracks one mechanism lane and the compounds that currently matter most inside it.
Lead read
Retatrutide
Retatrutide still defines the ceiling. Survodutide and mazdutide keep the GLP-1/glucagon side of the lane credible. The rest of the field is still proving it belongs in a conversation dominated by a few leaders.
Stage mix
2 phase 3 · 2 phase 1 · 1 approved · 1 preclinical
FormBlends separates early pipeline interest from late-stage, filed, and approved assets.
Direct answer
What is it?
Retatrutide is a phase 3 program from Eli Lilly built around GLP-1/GIP/Glucagon.
Why does it matter?
Triple agonists are one of the most important lanes in obesity because they are trying to move beyond GLP-1 appetite suppression alone. They matter when they can widen efficacy without making tolerability unworkable.
What should you read next?
What we know right now
Triple agonists are one of the most important lanes in obesity because they are trying to move beyond GLP-1 appetite suppression alone. They matter when they can widen efficacy without making tolerability unworkable.
Retatrutide still defines the ceiling. Survodutide and mazdutide keep the GLP-1/glucagon side of the lane credible. The rest of the field is still proving it belongs in a conversation dominated by a few leaders.
Right now this page is anchored by Retatrutide, Survodutide, Mazdutide, which is why the lane feels more concrete than a generic trend piece.
What is still uncertain
This topic already includes assets at approval or filing stage, so some of the commercial read is grounded in real regulatory progress rather than pure projection.
The next milestone is not basic approval. It is whether existing approvals broaden influence, prescribing relevance, or strategic spillover into the wider obesity market.
The biggest mistake in obesity pipeline content is treating strategic interest like commercial inevitability. This page is built to keep those two things separate.
What FormBlends is watching
- Whether late-stage efficacy keeps separating triple agonists from plain GLP-1 and dual-agonist products
- How much tolerability the market is willing to trade for extra weight loss
- Whether smaller or earlier triple programs can avoid becoming irrelevant beside Lilly's lead
Decision path
How should I interpret Triple Agonists Obesity Pipeline: The Compounds That Matter Through 2028?
This pipeline page is a decision aid for market context, not a patient access page. Use it to understand which mechanisms, companies, and trial stages are worth watching before comparing anything to available care.
- Topic
- triple agonists obesity pipeline
- Type
- Mechanism Tracker
- Tracked names
- 6
- Stage mix
- 2 phase 3 · 2 phase 1 · 1 approved · 1 preclinical
Step 1
Check maturity
This topic already includes assets at approval or filing stage, so some of the commercial read is grounded in real regulatory progress rather than pure projection.
Step 2
Watch the next signal
The next milestone is not basic approval. It is whether existing approvals broaden influence, prescribing relevance, or strategic spillover into the wider obesity market.
Open status hubStep 3
Compare to care today
Pipeline excitement should be separated from treatment decisions that require provider review, a legally available medication, and follow-up.
View current optionsHow this lane stacks up right now
A quick read on the compounds carrying the most weight on this page.
| Compound | Developer | Mechanism | Stage | Next step |
|---|---|---|---|---|
| Retatrutide | Eli Lilly | GLP-1/GIP/Glucagon | Phase 3 | Read status page |
| Survodutide | Boehringer/Zealand | GLP-1/Glucagon | Phase 3 | Read status page |
| Mazdutide | Innovent | GLP-1/Glucagon | Phase 3 / Approved China | Read status page |
| BI 3034701 | Boehringer/Gubra | Triple agonist | Phase 1 | Read status page |
| Novo Triple (UBT251) | Novo Nordisk | GLP-1/GIP/Glucagon | Phase 1b+ | Read status page |
| Kailera Triple | Kailera | GLP-1/GIP/Glucagon | Preclinical | Read status page |
Featured compounds in this lane
These are the names currently doing the real work in this part of the pipeline.
Triple agonists
Mazdutide
Innovent · Phase 3 / Approved China
GLP-1/Glucagon
Triple agonists
Novo Triple (UBT251)
Novo Nordisk · Phase 1b+
GLP-1/GIP/Glucagon
Related comparisons
Retatrutide vs Survodutide: Which Late-Stage Triple Agonist Matters More?
Retatrutide is still the bigger market-moving name because of its efficacy expectations, Lilly backing, and broader investor attention. Survodutide is not a weak second-place asset, but it currently looks more like a serious specialist challenger than the compound most likely to reset the whole obesity category.
Retatrutide vs Mazdutide: Global Triple-Agonist Leaders Compared
Retatrutide is the more important asset for the US obesity race, but mazdutide matters because it gives the market an earlier read on how GLP-1/glucagon programs can move once they leave the purely trial-stage bucket. If the question is category leadership, retatrutide wins. If the question is early commercial proof outside the US, mazdutide is more interesting.
Novo Triple vs Kailera Triple: Sponsored Early Triple Agonist vs Preclinical Challenger
Novo's triple program is the more credible asset today because it has sponsor weight and human-development momentum. Kailera's program is mainly a high-risk watchlist entry until it crosses into stronger human data territory.
BI 3034701 vs Mazdutide: Early Triple-Agnostic Hope vs Nearer GLP-1/Glucagon Reality
Mazdutide is the more tangible asset today. BI 3034701 is still a development-stage option on what might matter later. This is mostly a comparison between current relevance and future possibility.
FormBlends separates trial-stage tracking from actual patient availability.
Late-stage, filed, and approved assets are treated differently from early exploratory programs.
This page is meant to answer the query fast, then route readers into compound, status, and comparison pages for deeper analysis.